Chronic obstructive pulmonary disease is a common, burdensome and underdiagnosed condition in Australia. Spirometry is the basis of diagnosis and assessing severity in individual patients. Smoking cessation is the keystone for slowing the rate of decline in lung function. Pulmonary rehabilitation reduces breathlessness, anxiety and depression, and improves exercise capacity and quality of life. multidisciplinary care plans and individual self-management plans may help to prevent or manage crises. Inhaled bronchodilators provide symptom relief and may increase exercise capacity. Systemic steroids reduce the severity and shorten recovery from acute exacerbations. Patients with chronic obstructive pulmonary disease should receive influenza and pneumococcal vaccination.
Introduction
Chronic obstructive pulmonary disease (COPD) is the third leading cause of disease burden in Australia. The Australian Lung Foundation has conservatively estimated the annual direct costs to exceed $900 million. However, COPD was only the tenth most commonly managed chronic condition in general practice in 2003-04. There is substantial underdiagnosis and many patients are currently not receiving optimal medical care.
The Australian guidelines for COPD (COPD-X), first published in 2003 1 , were based upon the Global initiative for Obstructive Lung Disease (GOLD). 2 They are now updated quarterly 3 using the latest evidence from systematic reviews, particularly those published in the Cochrane Library.
C Confirm diagnosis and assess severity
Spirometry remains the basis for diagnosing and assessing the severity of COPD in individual patients 1 , however this test is underused in Australia. A recent systematic review found that spirometry, in addition to clinical examination, improved diagnostic accuracy compared to clinical examination alone.
The diagnosis of COPD rests on the demonstration of airflow limitation which is not fully reversible. On the other hand, if the airflow limitation is fully or substantially reversible, the patient should be treated as for asthma. 1 Published studies do not support the diagnostic use of trials of therapy with either corticosteroids (both inhaled and oral), short-or long-acting bronchodilators or oral theophylline in COPD. 4 
o optimise function

Bronchodilators
Inhaled bronchodilators provide symptom relief and may increase exercise capacity in patients with COPD. The dosage and frequency of short-acting beta 2 agonists (salbutamol, terbutaline) and anticholinergic drugs (ipratropium) can be titrated against the severity of the disease. 1 Long-acting bronchodilators can provide sustained symptom relief in patients with moderate to severe disease. They include the long-acting beta 2 agonists (salmeterol, eformoterol) which are inhaled twice daily and the long-acting inhaled anticholinergic drug tiotropium which is inhaled once daily.
Tiotropium has become first-line therapy in COPD. It has been shown to improve exercise capacity and quality of life.
A Cochrane review found that 14 patients would need to be treated with tiotropium for a year to prevent one exacerbation and 30 to prevent one hospitalisation compared to placebo and ipratropium. Controversially, a recent meta-analysis suggested that tiotropium might also be associated with reduced mortality and estimated that 278 patients would need to be treated to prevent one death. 5 
Combination therapy
The combination of short-acting beta 2 agonists and anticholinergics may be more effective and better tolerated than higher doses of either drug used alone. 
Comorbidities and complications
Most patients with COPD have other comorbid conditions.
Ischaemic heart disease and lung cancer share cigarette smoking as a common risk factor. There is increased mortality from respiratory failure, pneumonia, pulmonary vascular disease and heart failure. Anxiety and depression are also more common among patients with COPD. Corticosteroid treatment may contribute to the development of osteoporosis or diabetes.
The systemic effects of COPD include nutritional abnormalities and skeletal muscle wasting. 7 Many patients lose fat free mass, due to an increased basal metabolic rate that is not compensated for by increased dietary intake, or to the adverse effects of drugs (including beta 2 agonists and theophylline). Nutritional supplementation has not been associated with any improvement in lung function or exercise capacity. Causes of muscle weakness include physical deconditioning, systemic inflammation, oxidative stress, corticosteroid adverse effects, hypoxia, electrolyte disturbances and many other factors. Physical deconditioning can be effectively reduced by pulmonary rehabilitation.
Pulmonary rehabilitation
Pulmonary rehabilitation reduces breathlessness, anxiety and depression, and improves exercise capacity and quality of life in COPD. Comprehensive integrated rehabilitation programs include exercise training, patient education and psychosocial support. Long recommended for patients with moderate to severe disease, there is now evidence that exercise training also benefits those with milder disease. An online toolkit is available to assist health professionals to implement pulmonary rehabilitation programs. 8
Surgery
In patients with predominantly upper lobe emphysema and low baseline exercise capacity, who remain disabled following pulmonary rehabilitation, there may be a limited place for lung volume reduction surgery. However, high-risk patients with more widespread emphysema should not be referred for surgery because of increased mortality and negligible functional gain. 9 
P Prevent deterioration
Smoking cessation is the keystone for slowing the rate of decline of forced expiratory volume in one second (FEV 1 ) in COPD. The behavioural and pharmacological interventions available to promote complete cessation of smoking and maintain abstinence were reviewed in COPD-X. 1 Systemic corticosteroids have a very limited role in COPD other than in acute exacerbations. Inhaled corticosteroids are associated with a modest reduction in the rate of FEV 1 decline which is of uncertain clinical significance. 3 A slightly greater effect was seen in trials that gave patients 800 microgram or more of budesonide or 1000 microgram of fluticasone per day.
The longer-term adverse events associated with these high doses of inhaled corticosteroids are yet to be determined, so the optimum dose is unknown. A recent systematic review which pooled individual patient data from seven clinical trials found a 25% reduction in mortality among patients treated with inhaled steroids compared to placebo. 10 We estimate that 94 patients would need to be treated with inhaled steroids for two years to prevent one death. Patients with COPD should receive annual influenza and five-yearly pneumococcal vaccination. 11
Domiciliary oxygen
Long-term continuous oxygen therapy
Long-term continuous oxygen therapy for at least 15 hours a day has been shown to reduce mortality in patients whose arterial oxygen (PaO 2 ) is consistently ≤ 55 mmHg, or 55-59 mmHg with evidence of hypoxic sequelae such as polycythaemia, pulmonary hypertension or cor pulmonale.
Oxygen may also improve exercise capacity and mental state. Follow-up at home after discharge from hospital helps to continue the management begun within the acute environment.
Intermittent oxygen therapy
However, there is no current evidence to show a benefit from nurse-led chronic disease management for people with COPD.
Conclusion
The challenge remains to improve the recognition and management of COPD in Australia. A large multicentre trial of combination therapy is due to report shortly. However, there is a pressing need for more randomised controlled trials of nondrug therapies for COPD. 
Self-test questions
Comment
Acute interstitial nephritis is due to a hypersensitivity reaction and is typically associated with reversible acute renal failure.
Drugs account for 71% of cases of acute interstitial nephritis. 1 Medicines commonly implicated include non-steroidal were associated with omeprazole, 12 with esomeprazole, 6 with pantoprazole and 14 with rabeprazole. The duration of proton pump inhibitor treatment before presentation is usually between two weeks and nine months. 4 The temporal relationship in this case suggests that omeprazole was the most likely cause of interstitial nephritis, although the possibility that amoxycillin, pantoprazole or the NSAID were implicated cannot be excluded.
Recommendation
Maintain a high index of suspicion for interstitial nephritis in patients who develop acute renal failure while on a proton pump inhibitor. The diagnosis can only be confirmed on renal biopsy. Management involves drug withdrawal and supportive treatment. The efficacy of corticosteroids has not been demonstrated in controlled trials. 4 
